Facts and Hopes for Immunotherapy in Renal Cell Carcinoma

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Immunotherapy has made a significant impact in many tumors, including renal cell carcinoma (RCC). RCC has been known to be immunoresponsive since the cytokine era of IFNa and IL2, but only a small number of patients had durable clinical benefit. Since then, discoveries of key tumor drivers, as well as an understanding of the contribution of angiogenesis and the tumor microenvironment (TME), has led to advances in drug development, ultimately transforming patient outcomes. Combinations of anti-angiogenic agents with immune checkpoint inhibitors are now standard of care. Current challenges include patient selection for immunotherapy combinations, resistance acquisition, and optimally sequencing therapies. Further discoveries about RCC biology, the TME, and resistance mechanisms will likely pave the way for the next generation of therapies.

Original languageEnglish (US)
Pages (from-to)5013-5020
Number of pages8
JournalClinical Cancer Research
Issue number23
StatePublished - Dec 1 2022

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Facts and Hopes for Immunotherapy in Renal Cell Carcinoma'. Together they form a unique fingerprint.

Cite this